Alturaif Sumayya A, Alhusaini Ahlam, Sarawi Wedad, Hasan Iman, Alsaab Juman, Ali Rehab, Mohammed Raeesa, Alotaibi Sahar S, Almutairi Faris, Alsaif Shaikha, Alsultan Ebtesam, Aljasas Ebtesam, Alsanea Sary
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
Department of Anatomy, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia.
Pharmaceuticals (Basel). 2025 Jun 1;18(6):828. doi: 10.3390/ph18060828.
Methotrexate (MTX) is a widely used therapeutic agent for inflammatory and malignant diseases; however, its prolonged use is associated with hepatotoxicity through mechanisms that remain inadequately understood. This study aims to elucidate these mechanisms and assess the hepatoprotective potential of indole-3-acetic acid (IAA). Rats were allocated into five groups: control (group 1), IAA-treated (group 2), MTX-treated (group 3), quercetin (QUR) + MTX (group 4), and IAA + MTX (group 5). Hepatic function was assessed through the evaluation of serum liver enzymes, oxidative stress, and inflammatory and apoptotic markers using biochemical, molecular, histopathological, and immunohistochemical analyses. The MTX-treated group demonstrated a significant increase in hepatic oxidative stress, inflammation, and apoptotic markers. Co-administration of IAA or QUR with MTX markedly reduced malondialdehyde (MDA) levels, while enhancing glutathione (GSH) levels and superoxide dismutase (SOD) activity. Moreover, hepatic inflammatory markers, including TNF-α, IL-6, and IL-1β, were significantly decreased in the IAA- and QUR-treated groups. Immunohistochemical analysis further revealed a reduced expression of NF-κB, TLR4, and caspase-3 in hepatic tissues following QUR-MTX or IAA-MTX treatments. IAA exhibited hepatoprotective effects against MTX-induced liver injury, comparable to QUR, by modulating the TLR4/NF-κB/caspase-3 pathway. These findings highlight its potential clinical application in reducing MTX-associated hepatic complications.
甲氨蝶呤(MTX)是一种广泛用于治疗炎症性疾病和恶性疾病的药物;然而,其长期使用会通过一些尚未完全了解的机制导致肝毒性。本研究旨在阐明这些机制,并评估吲哚 - 3 - 乙酸(IAA)的肝保护潜力。将大鼠分为五组:对照组(第1组)、IAA处理组(第2组)、MTX处理组(第3组)、槲皮素(QUR)+MTX组(第4组)和IAA + MTX组(第5组)。通过生化、分子、组织病理学和免疫组织化学分析,评估血清肝酶、氧化应激、炎症和凋亡标志物,以评价肝功能。MTX处理组的肝脏氧化应激、炎症和凋亡标志物显著增加。IAA或QUR与MTX联合给药可显著降低丙二醛(MDA)水平,同时提高谷胱甘肽(GSH)水平和超氧化物歧化酶(SOD)活性。此外,IAA和QUR处理组的肝脏炎症标志物,包括TNF-α、IL-6和IL-1β,显著降低。免疫组织化学分析进一步显示,QUR - MTX或IAA - MTX处理后,肝组织中NF-κB、TLR4和caspase-3的表达降低。IAA通过调节TLR4/NF-κB/caspase-3途径,对MTX诱导的肝损伤具有与QUR相当的肝保护作用。这些发现突出了其在减少MTX相关肝脏并发症方面的潜在临床应用价值。
Front Endocrinol (Lausanne). 2025-6-6
Medicina (Kaunas). 2025-6-4
Cochrane Database Syst Rev. 2017-5-8
Curr Opin Pharmacol. 2022-6
Gastroenterol Res Pract. 2021-11-10